Perspective Therapeutics (NYSE:CATX) Sees Large Volume Increase – What’s Next?

by · The Cerbat Gem

Perspective Therapeutics, Inc. (NYSE:CATX – Get Free Report) shares saw unusually-strong trading volume on Monday . Approximately 307,892 shares traded hands during mid-day trading, a decline of 55% from the previous session’s volume of 682,754 shares.The stock last traded at $12.59 and had previously closed at $12.66.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on CATX. Oppenheimer reaffirmed an “outperform” rating and set a $22.00 price target on shares of Perspective Therapeutics in a report on Friday. Truist Financial began coverage on Perspective Therapeutics in a report on Wednesday, September 25th. They issued a “buy” rating and a $21.00 price target for the company. Royal Bank of Canada reduced their price target on shares of Perspective Therapeutics from $29.00 to $27.00 and set an “outperform” rating on the stock in a research report on Friday, August 16th. Cantor Fitzgerald restated an “overweight” rating on shares of Perspective Therapeutics in a research report on Monday, September 9th. Finally, Wedbush started coverage on shares of Perspective Therapeutics in a research report on Tuesday, October 1st. They set an “outperform” rating and a $25.00 target price on the stock. Eight investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Perspective Therapeutics currently has an average rating of “Buy” and an average price target of $21.43.

View Our Latest Report on CATX

Perspective Therapeutics Stock Performance

The firm has a 50 day moving average of $13.82.

Perspective Therapeutics (NYSE:CATX – Get Free Report) last posted its quarterly earnings results on Monday, August 12th. The company reported ($0.17) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.04. The company had revenue of $0.53 million during the quarter. Equities analysts anticipate that Perspective Therapeutics, Inc. will post -0.87 EPS for the current fiscal year.

Institutional Trading of Perspective Therapeutics

A number of hedge funds have recently modified their holdings of CATX. Janus Henderson Group PLC acquired a new position in shares of Perspective Therapeutics in the 1st quarter valued at approximately $15,511,000. Affinity Asset Advisors LLC acquired a new position in shares of Perspective Therapeutics in the first quarter valued at approximately $6,069,000. Vanguard Group Inc. increased its position in shares of Perspective Therapeutics by 34.6% during the first quarter. Vanguard Group Inc. now owns 17,780,106 shares of the company’s stock worth $21,158,000 after acquiring an additional 4,566,356 shares in the last quarter. Ally Bridge Group NY LLC bought a new stake in Perspective Therapeutics in the 2nd quarter valued at $3,951,000. Finally, WealthPLAN Partners LLC acquired a new position in Perspective Therapeutics in the 2nd quarter worth $1,695,000. 54.66% of the stock is currently owned by institutional investors and hedge funds.

Perspective Therapeutics Company Profile

(Get Free Report)

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.

Recommended Stories